Analyst Krishna Shankar of Roth Capital upgraded Intel Corporation (INTC) from Neutral to Buy, and boosted his price target on INTC from $28.00 to $35.
Roth Capital reiterated coverage yesterday on Uranium Resources Inc. (URRE) with a Buy rating and $4.
In a report published today, Roth Capital analyst Ed Arce resumed coverage on Conatus Pharmaceuticals Inc. (CNAT) with a Buy rating and $19.
In a research note issued this morning, Roth Capital maintained coverage with a “Buy” rating on Motorcar Parts of America, Inc. (MPAA) and a price target of $30.
In a research note issued this morning, Roth Capital reiterated coverage with a “Buy” rating on Capstone Turbine Corp. (CPST) and a price target of $1.
In a research note issued this morning, H.C.
In a research note released this morning, Janney Montgomery Scott reiterated coverage on Vertex Pharmaceuticals (VRTX) with an Outperform rating and $90 fair value estimate. A data …
In a research note released today, William Blair reiterated coverage on Encore Capital Group, Inc (ECPG) with an Outperform rating. Blair analyst Robert Napoli has increased confidence in Encore’s long-term growth …
In a research note issued today, Wedbush reiterated coverage with a “Buy” rating on Smith & Wesson (SWHC), and a price target of $20.00 a share.
Ariad Pharmaceuticals (ARIA) had its price target reduced by UBS from $7.50 to $7.